These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
469 related articles for article (PubMed ID: 19743942)
1. Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective. Bessette L; Risebrough N; Mittmann N; Roussy JP; Ho J; Zlateva G J Med Econ; 2009 Sep; 12(3):246-58. PubMed ID: 19743942 [TBL] [Abstract][Full Text] [Related]
2. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Maetzel A; Krahn M; Naglie G Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781 [TBL] [Abstract][Full Text] [Related]
4. A cost-effectiveness analysis of celecoxib compared with diclofenac in the treatment of pain in osteoarthritis (OA) within the Swedish health system using an adaptation of the NICE OA model. Brereton N; Pennington B; Ekelund M; Akehurst R J Med Econ; 2014 Sep; 17(9):677-84. PubMed ID: 24914585 [TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of nonsteroidal anti-inflammatory drug strategies in rheumatoid arthritis. Inotai A; Mészáros A Int J Technol Assess Health Care; 2009 Apr; 25(2):190-5. PubMed ID: 19366498 [TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470 [TBL] [Abstract][Full Text] [Related]
7. Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in the Netherlands. Al MJ; Maniadakis N; Grijseels EW; Janssen M Value Health; 2008; 11(4):589-99. PubMed ID: 18194404 [TBL] [Abstract][Full Text] [Related]
8. Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib? Rahme E; Hunsche E; Toubouti Y; Chabot I Arthritis Rheum; 2006 Feb; 55(1):27-34. PubMed ID: 16463408 [TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis. Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of duloxetine in chronic low back pain: a Quebec societal perspective. Wielage R; Bansal M; Wilson K; Klein R; Happich M Spine (Phila Pa 1976); 2013 May; 38(11):936-46. PubMed ID: 23250234 [TBL] [Abstract][Full Text] [Related]
11. Celecoxib versus a non-selective NSAID plus proton-pump inhibitor: what are the considerations? Chen JT; Pucino F; Resman-Targoff BH J Pain Palliat Care Pharmacother; 2006; 20(4):11-32. PubMed ID: 17182503 [TBL] [Abstract][Full Text] [Related]
12. An economic model of long-term use of celecoxib in patients with osteoarthritis. Loyd M; Rublee D; Jacobs P BMC Gastroenterol; 2007 Jul; 7():25. PubMed ID: 17610716 [TBL] [Abstract][Full Text] [Related]
13. [Cost-effectiveness analysis of celecoxib versus non-selective non-steroidal anti-inflammatory drug therapy for the treatment of osteoarthritis in Spain: A current perspective]. De Lossada A; Oteo-Álvaro Á; Giménez S; Oyagüez I; Rejas J Semergen; 2016; 42(4):235-43. PubMed ID: 26006311 [TBL] [Abstract][Full Text] [Related]
14. Gastroprotective strategies in chronic NSAID users: a cost-effectiveness analysis comparing single-tablet formulations with individual components. de Groot NL; Spiegel BM; van Haalen HG; de Wit NJ; Siersema PD; van Oijen MG Value Health; 2013; 16(5):769-77. PubMed ID: 23947970 [TBL] [Abstract][Full Text] [Related]
15. Cost-utility analysis and economic burden of knee osteoarthritis treatment: the analysis from the real clinical practice. Turajane T; Chaweevanakorn U; Sungkhun P; Larbphiboonpong V; Wongbunnak R J Med Assoc Thai; 2012 Oct; 95 Suppl 10():S98-104. PubMed ID: 23451446 [TBL] [Abstract][Full Text] [Related]
16. Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors. Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC Am J Manag Care; 2002 Oct; 8(15 Suppl):S401-13. PubMed ID: 12416790 [TBL] [Abstract][Full Text] [Related]
17. Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level. Varas-Lorenzo C; Maguire A; Castellsague J; Perez-Gutthann S Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):366-76. PubMed ID: 16897817 [TBL] [Abstract][Full Text] [Related]
18. Arthritis treatment in Hong Kong--cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents. You JH; Lee KK; Chan TY; Lau WH; Chan FK Aliment Pharmacol Ther; 2002 Dec; 16(12):2089-96. PubMed ID: 12452942 [TBL] [Abstract][Full Text] [Related]
19. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Spiegel BM; Targownik L; Dulai GS; Gralnek IM Ann Intern Med; 2003 May; 138(10):795-806. PubMed ID: 12755551 [TBL] [Abstract][Full Text] [Related]
20. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study. Rahme E; Bardou M; Dasgupta K; Toubouti Y; Ghosn J; Barkun AN Rheumatology (Oxford); 2007 Feb; 46(2):265-72. PubMed ID: 16844699 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]